建立了液相色谱-串联质谱（LC-MS / MS）检测人血浆脂蛋白唾液酸的方法，并比较了糖尿病患者与健康人血浆脂蛋白唾液酸的差异。采用 pH =2的醋酸水解唾液酸，高速离心后采用优化的条件进行 LC-MS / MS 分析。结果表明：在负离子模式下，唾液酸的检出限和定量限分别为7.4和24.5 pg。唾液酸在2.5~80 ng / mL 范围内呈良好的线性关系，相关系数 R2大于0.998。糖尿病患者（平均年龄51.6岁）和健康人（平均年龄50.7岁）血浆中唾液酸的含量分别为（548.3±88.9）和（415.3±55.5）mg / L；两组实验人群中极低密度脂蛋白、低密度脂蛋白和高密度脂蛋白唾液酸的含量分别为（4.91±0.19）、（6.95±0.28）、（3.61±0.22）μg / mg和（2.90±0.27）、（7.03±0.04）、（2.40±0.09）μg / mg。糖尿病患者极低密度脂蛋白和高密度脂蛋白唾液酸含量显著高于同龄健康人水平（ P<0.01）。该法可快速检测血浆中脂蛋白唾液酸含量，省时省力。
A liquid chromatography-tandem mass spectrometry ( LC-MS / MS ) method was established to quantify sialic acid( N-acetylneuraminic acid,NANA ) from lipoproteins and human plasma. The method was used to investigate the different contents of NANA from lipo-proteins between diabetic with an average age of 51. 6 years and healthy participants with an average age of 50. 7 years. The NANA from lipoprotein samples was hydrolyzed by acetic acid (pH = 2)at 80 ℃ for 2 h and analyzed by the optimized LC-MS / MS method after high speed centrifugation and filtration. The limits of detection and quantification of NANA were 7. 4 and 24. 5 pg,respectively. The linear range was 2. 5-80 ng / mL for NANA and the correlation coeffi-cient(R2 )was more than 0. 998. The levels of NANA in the plasma of type Ⅱ diabetics and healthy participants were(548. 3±88. 9)and(415. 3±55. 5)mg / L,respectively;and the levels of NANA from very low density lipoproteins(VLDL),low density lipoproteins(LDL),and high density lipoproteins(HDL)of the type Ⅱ diabetics and the healthy participants were( 4. 91 ± 0. 19),(6. 95± 0. 28),(3. 61 ± 0. 22)μg / mg and( 2. 90 ± 0. 27),( 7. 03 ± 0. 04),( 2. 40 ± 0. 09)μg / mg,respectively. The sialic acid levels of VLDL and HDL from the type Ⅱ diabetics were markedly higher than those of the corresponding healthy participants with the similar ages(P<0. 01). The method can rapidly determine the sialic acid from lipoproteins,and is reproducible and time saving.
参考文献
| [1] | Dodani S;Grice D G;Joshi S.[J].J Clin Lipidol,20093(02):70. |
| [2] | Millar J S;Anber V;Shepherd J.[J].Atherosclerosis,1999145:253. |
| [3] | 丛培旭;李兆杰;徐杰.[J].色谱,201331(05):399. |
| [4] | Camejo G;López A;López F.[J].Atherosclerosis,198555:93. |
| [5] | Stratton P D;Lumb P J;Paganga G.[J].Atherosclerosis,2001154:285. |
| [6] | Gavella M;Lipovac V;Car A.[J].Acta Diabetol,200340:95. |
| [7] | Serdar Z;Yesilbursa D;Dirican M.[J].Cell Biochem Funct,200725:655. |
| [8] | Anumula K R.[J].Anal Biochem,1995230:24. |
| [9] | Hikita T;Tadano-Aritomi K;Iida-Tanaka N.[J].Anal Bio-chem,2000281:193. |
| [10] | Reuter G;Pfeil R;Stoll S.[J].Eur J Biochem,1983134:139. |
| [11] | Ortner K;Buchberger W.[J].Electrophoresis,200829(10):2233. |
| [12] | Rajendiran S;Lakshamanappa H S;Zachariah B.[J].Am J Trop Med Hyg,200879(03):372. |
| [13] | Kontush A;John Chapman M.[J].Pharmacol Rev,200658:342. |
| [14] | Phillips C;Owens D;Collins P.[J].Atherosclerosis,2005181:109. |
| [15] | Iijima R;Takahashi H;Namme R.[J].FEBS Lett,2004561:163. |
| [16] | Ogasawara Y;Namai T;Yoshino F.[J].FEBS Lett,2007581(13):2473. |
| [17] | Lindbohm N;Gylling H;Miettinen T A.[J].J Lipid Res,200041:1110. |
| [18] | Filipovic I;Schwarzmann G;Mraz W.[J].Eur J Bio-chem,197993:51. |
| [19] | 解鸿蕾;李春;刘宁.[J].色谱,201331(08):781. |
| [20] | 侯向昶;朱丽萍;刘春生.[J].现代食品科技,201329(07):1706. |
- 下载量()
- 访问量()
- 您的评分：
-
10%
-
20%
-
30%
-
40%
-
50%